BioNTech (NASDAQ:BNTX) Given New $143.00 Price Target at BMO Capital Markets

BioNTech (NASDAQ:BNTX) had its price objective boosted by BMO Capital Markets from $130.00 to $143.00 in a report issued on Tuesday,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Several other equities analysts have also recently weighed in on the company. Berenberg Bank started coverage on BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. lowered their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.65.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $98.39 on Tuesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $116.45 and its two-hundred day simple moving average is $113.13. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a market cap of $23.59 billion, a PE ratio of -46.85 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period last year, the business earned $1.90 EPS. The business’s revenue was down 19.5% on a year-over-year basis. As a group, analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. increased its holdings in BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock worth $221,000 after acquiring an additional 128 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Probity Advisors Inc. increased its holdings in BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after acquiring an additional 154 shares during the last quarter. Midwest Professional Planners LTD. increased its holdings in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock worth $462,000 after acquiring an additional 222 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in BioNTech by 3.9% during the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after buying an additional 224 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.